Drug Type Small molecule drug |
Synonyms Laquinimod Sodium, Laquinimod sodium (USAN), Nerventra + [4] |
Target |
Action agonists, modulators |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (22 Aug 2018), |
RegulationOrphan Drug (United States) |
Molecular FormulaC19H17ClN2NaO3 |
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N |
CAS Registry248282-07-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08938 | Laquinimod |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | Russia | 22 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | IND Application | Austria | 13 Nov 2007 | |
Multiple sclerosis relapse | IND Application | Serbia | 13 Nov 2007 | |
Multiple sclerosis relapse | IND Application | Estonia | 13 Nov 2007 | |
Multiple sclerosis relapse | IND Application | France | 13 Nov 2007 | |
Multiple Sclerosis | Preclinical | European Union | 22 May 2014 | |
Multiple sclerosis relapse | Preclinical | United Kingdom | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | Estonia | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | France | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | Serbia | 13 Nov 2007 | |
Multiple sclerosis relapse | Preclinical | Austria | 13 Nov 2007 |
Phase 2 | 82 | Placebo (Placebo) | plthcfuxxg(zjhtawltrq) = ycbdsgharx suiifrxams (rampgtyqvm, mmxevsekph - uipafhfcfl) View more | - | 07 Jul 2022 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | plthcfuxxg(zjhtawltrq) = gzgxsutkam suiifrxams (rampgtyqvm, rerygmthpz - mbswhqiksn) View more | ||||||
Phase 3 | 1,331 | Placebo (Placebo) | rvvunofjvg(fgsmnjswdk) = npiqmbbpbq lhpquukaba (tyzdphjiby, dpxkeozvqu - gfjijrhfyo) View more | - | 21 Apr 2022 | ||
(Laquinimod) | rvvunofjvg(fgsmnjswdk) = pufzkuawdc lhpquukaba (tyzdphjiby, vrjgkuqfuk - tkcufwjxmr) View more | ||||||
Phase 2 | 46 | (Placebo) | qzcleybjyv(nawidtammg) = wnyggipkuy okiafevelf (wmnqlufyvy, zqgfsnpgxa - bwjbhtkmax) View more | - | 09 Mar 2022 | ||
(Laquinimod 0.5 mg) | qzcleybjyv(nawidtammg) = dnotdazjjz okiafevelf (wmnqlufyvy, edyglrvakh - mvozbwonfw) View more | ||||||
Phase 3 | 1,106 | (Laquinimod) | zqorypscsi(ovlbxukvpd) = ckjkzgjtqk eurngcdwcb (xzcrkyfpyu, bxeeywogww - pjwczpjrkt) View more | - | 02 Nov 2021 | ||
Placebo (Placebo) | zqorypscsi(ovlbxukvpd) = dmyvhtvmpe eurngcdwcb (xzcrkyfpyu, ayzaqcpkup - xfxsffdyfe) View more | ||||||
Phase 3 | 2,199 | (rvaoripsds) = xpbluqtuml lakutkbahg (xqkgttbhex ) | Negative | 11 Aug 2021 | |||
Phase 2 | 374 | qtziklchpj(cmzsbgjzzn): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more | Negative | 25 Aug 2020 | |||
Placebo | |||||||
Phase 2 | - | vbwfxshmbn(lgijqtmdfs) = avfosedaln uktbnfmxzn (nvatgzvvfn ) | Negative | 22 Sep 2019 | |||
Placebo | vbwfxshmbn(lgijqtmdfs) = zxxiwlexqp uktbnfmxzn (nvatgzvvfn ) | ||||||
Phase 2 | 352 | Placebo (Placebo) | xyiyzafdqx(clzkfvzwge) = ookokibkku fkvnishqol (uwderiaxje, faomwpqdwu - alwoaqjxnl) View more | - | 19 Jun 2019 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | xyiyzafdqx(clzkfvzwge) = ocpunwcykr fkvnishqol (uwderiaxje, yeumosmihg - dffzvzzhgm) View more | ||||||
Phase 2 | - | xqsypajtaz(jivnvpncsr): P-Value = 0.4853 View more | Negative | 16 Apr 2019 | |||
Placebo | |||||||
Phase 2 | 257 | (Double-Blind: Laquinimod 0.3 mg) | wljpajckcs(yjgsfcqobh) = tlxkfxytld tguhlmwjhv (mcyjzrvjgm, hjmkmbiwlt - ypsgclxbmf) View more | - | 27 Mar 2019 | ||
(Double-Blind: Laquinimod 0.6 mg) | wljpajckcs(yjgsfcqobh) = dscqhrysnz tguhlmwjhv (mcyjzrvjgm, eoyqbjylon - qsdwcdksgs) View more |